Johns Hopkins ABX Guide
Sofosbuvir + Ledipasvir
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotypes 1, 4, 5 or 6 infections without cirrhosis or with compensated cirrhosis.
- Also, genotype 1 with decompensated cirrhosis in combination with ribavirin.
- Genotype 1 or 4 in liver transplant recipients without cirrhosis or with compensated cirrhosis with ribavirin.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 8, 2023
Citation
Auwaerter, Paul G, and Janessa Smith M Smith. "Sofosbuvir + Ledipasvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2023. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540671/6/Sofosbuvir_+_Ledipasvir.
Auwaerter PG, Smith JM. Sofosbuvir + Ledipasvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540671/6/Sofosbuvir_+_Ledipasvir. Accessed December 26, 2024.
Auwaerter, P. G., & Smith, J. M. (2023). Sofosbuvir + Ledipasvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540671/6/Sofosbuvir_+_Ledipasvir
Auwaerter PG, Smith JM. Sofosbuvir + Ledipasvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2023. [cited 2024 December 26]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540671/6/Sofosbuvir_+_Ledipasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Sofosbuvir + Ledipasvir
ID - 540671
A1 - Auwaerter,Paul,M.D.
AU - Smith,Janessa Smith,PharmD, BCPS
Y1 - 2023/07/08/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540671/6/Sofosbuvir_+_Ledipasvir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
